A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients
Information source: GlaxoSmithKline
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Phase: Phase 1
Sponsored by: GlaxoSmithKline
Official(s) and/or principal investigator(s):
GSK Clinical Trials, MD, Study Director, Affiliation: GlaxoSmithKline
The primary goal of this study is to identify a gene or panel of genes which are
differentially expressed in lung cells and tissue from asthmatic patients following
administration of Ipratropium bromide and eiTher nebulised Albuterol or saline. Each subject
in this study will undergo two bronchoscopies.
Official title: A Study to Identify a Transcriptomic Profile Indicative of Cycle AMP Pathway Activation in the Lung
Study design: Natural History, Longitudinal, Defined Population, Prospective Study
Minimum age: 18 Years.
Maximum age: 45 Years.
- Have a history of intermittant asthma.
- Have asthma symptoms less than once per week.
- Have no other significant disease.
- Do not take regular oral or inhaled steroids.
- Are a non-smoker for the past 12 months with a pack history of less than 5 years.
- Have a history of drug or alcohol abuse.
- Have poorly controlled asthma or a history of life-threatening asthma.
- Have a history of hypersensitivity to bronchodilators.
- Are unable to abstain from inhaled steroids from 14 days prior to the first study
visit until completion of the study.
- Have received oral steroids within 3 months of study entry.
- Have been hospitalized for your asthma within 3 months of study entry.
- Have had treatment with an investigational drug within 30 days or 5 half-lives
(whichever is longer) preceding the first dose of study medication.
Locations and Contacts
GSK Clinical Trials Call Center, Philadelphia, Pennsylvania 19104, United States
Starting date: December 2005
Last updated: April 18, 2007